Cargando…
Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review
With the development of evidence-based medicine, clinical trials have become necessary for investigating and validating the efficacy of new treatments. Over the past 10 years, several clinical trials of new anticancer agents have been designed and launched in China; this has greatly promoted the dev...
Autores principales: | Su, Shan, Wu, Yi-Long |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547513/ https://www.ncbi.nlm.nih.gov/pubmed/28784178 http://dx.doi.org/10.1186/s13045-017-0514-z |
Ejemplares similares
-
Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
por: Pisick, Evan, et al.
Publicado: (2004) -
Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
por: Rozkiewicz, Dariusz, et al.
Publicado: (2023) -
Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials
por: Kim, Sungkyoung, et al.
Publicado: (2014) -
Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
por: Vavalà, Tiziana, et al.
Publicado: (2019) -
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
por: Liu, Si-Yang, et al.
Publicado: (2017)